US-based clinical data exchange company MRO has acquired Q-Centrix, an enterprise clinical data management platform previously owned by TPG Growth.

Q-Centrix is a comprehensive data management platform designed to reduce complexity, expedite decisions and advance clinical outcomes.

MRO said the acquisition would enable hospitals and health systems to convert fragmented clinical data into actionable insights, expediting the exchange of clinical data across the sector.

The deal is expected to create scalable value for healthcare providers, payers and life sciences, supporting more precise decision-making and broader clinical applications.

MRO CEO Jason Brown said: “At MRO, we believe there is tremendous untapped value in unlocking and leveraging clinical data that resides in fragmented, siloed systems today.

“Combining MRO’s leading clinical data exchange solutions and Q-Centrix’s clinical data management capabilities creates a category-defining, fit-for-purpose platform, enabling high fidelity, low latency acquisition, abstraction, curation and exchange of clinical data to power better patient care and reduce costs across the healthcare ecosystem.”

The combined entity will provide services to more than 2,000 health systems and hospitals, as well as over 7,000 clinics and almost 250 payers.

By enriching and curating clinical data, MRO and Q-Centrix aim to deliver scalable value, facilitating precise decision-making and wider clinical applications.

Q-Centrix CEO Milton Silva-Craig said: “MRO and Q-Centrix share a commitment to advancing the industry in service of our customers.

“That focus is fuelling the creation of a first-of-its-kind platform—seamlessly integrating systems and delivering structured, highly valuable data sets to support clinical care, operational performance, breakthrough research, and regulatory compliance.

“Purpose-built around our customers’ most pressing needs, this is innovation where it matters most.”

The acquisition is supported by healthcare technology investors such as private equity company Parthenon Capital, which has reaffirmed its support for MRO with a new investment.

The parties have not disclosed the value of the deal.